H.C. Wainwright lowered the firm’s price target on BioXcel Therapeutics to $7 from $10 and keeps a Buy rating on the shares. The company reported a top- and bottom-line beat but slower revenue growth is anticipated due to operating constraints, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTAI:
- BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
- Bioxcel Therapeutics (BTAI) Q2 Earnings Cheat Sheet
- Biotech Alert: Searches spiking for these stocks today
- BioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual Film
- BioXcel Therapeutics sees Q2 net revenues from sales of IGALMI of $1.1M